Jeremy Grantham Gritstone Bio, Inc. Call Options Transaction History
Grantham, Mayo, Van Otterloo & Co. LLC
- $31.4 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GRTS
# of Institutions
62Shares Held
35.4MCall Options Held
395KPut Options Held
132K-
Morgan Stanley New York, NY10.3MShares$308,8690.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.92MShares$147,6050.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.64MShares$139,3170.0% of portfolio
-
Versant Venture Management, LLC San Francisco, CA3.56MShares$106,8345.41% of portfolio
-
Siren, L.L.C. New York, NY3.32MShares$99,5420.1% of portfolio
About Gritstone bio, Inc.
- Ticker GRTS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,006,896
- Market Cap $2.19M
- Description
- Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...